Related Experiment Videos
Monoclonal anti-D for immunoprophylaxis
1International Blood Group Reference Laboratory, National Blood Service, Southmead Road, Bristol BS10 5ND, UK. marion.scott@nbs.nhs.uk
Vox Sanguinis
|March 21, 2002
Summary
Routine antenatal anti-D prophylaxis is crucial, but supply and safety concerns exist for polyclonal anti-D. Human monoclonal anti-D offers a potential alternative, with ongoing research into its development and safety for prophylactic use.
Area of Science:
- Immunology
- Hematology
- Biotechnology
Background:
- Routine antenatal anti-D prophylaxis is standard practice.
- Concerns exist regarding the supply and safety of polyclonal anti-D immunoglobulin.
Purpose of the Study:
- To review the development and considerations for human monoclonal anti-D for prophylactic use.
- To address the limitations of current anti-D prophylaxis.
Main Methods:
- Production of human monoclonal anti-D using Epstein-Barr virus (EBV)-transformed B cells and myeloma fusions.
- Application of molecular biology techniques for monoclonal anti-D production.
- Characterization of monoclonal antibodies (mAbs) for specificity and in vitro activity.
Main Results:
- Two specific mAbs demonstrated red cell clearance and immunosuppression in male volunteers.
- Various methods for producing human monoclonal anti-D have been developed and characterized.
Conclusions:
- Human monoclonal anti-D presents a promising alternative to polyclonal anti-D for antenatal prophylaxis.
- Further considerations for the future development and safety of monoclonal anti-D are necessary.